Manitol Viaflo Baxter (Mannitol)

Mannitol acts as an osmotic agent that remains largely unmetabolized in the renal tubules. By creating an osmotic gradient, it draws water into the tubular lumen, increasing urine output, and pulls fluid from brain or eye tissues into the bloodstream, thereby reducing pressure in those compartments.

The specific dose of Manitol Viaflo Baxter is determined by the prescribing clinician based on the patient’s condition, weight, renal function and therapeutic goals. Healthcare professionals calculate the appropriate infusion rate and total volume for each individual case.

Safety data for mannitol in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mannitol is a widely used osmotic diuretic with a rapid onset of action and predictable renal excretion. Compared with hypertonic saline, mannitol provides both diuretic and pressure‑reducing effects, but may carry a higher risk of electrolyte disturbances. Choice of agent depends on the clinical scenario and physician preference.

Manitol Viaflo Baxter should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Inspect for particulate matter before use.

The product is supplied as a sterile solution for injection and is administered intravenously. It can be given as a slow infusion or bolus, depending on the indication and the prescribing clinician’s protocol. Administration should be performed by qualified healthcare personnel in a controlled setting.

Serious risks include acute renal failure, severe electrolyte imbalances (especially hypernatremia or hyponatremia), pulmonary edema from fluid overload, and rare anaphylactic reactions. Patients should be closely monitored for changes in renal function, fluid status and vital signs during treatment.

Mannitol is contraindicated in patients with known hypersensitivity to mannitol, severe renal impairment, active pulmonary edema, uncontrolled heart failure, or severe electrolyte disturbances. It should also be used with caution in individuals with intracranial hemorrhage where rapid osmotic shifts could worsen the condition.